Currently available drugs that target PD-1/PD-L1 pathway

DrugsApproved indicationDosageRoute of administrationSide effects
Nivolumab (brand name “OPDIVO®”, fully human IgG4 mAb)Metastatic NSCLC, metastatic melanoma, CHL, malignant pleural mesothelioma, RCC, HNSCC, urothelial carcinoma, HCC, esophageal cancer, dMMR, or MSI-H metastatic colorectal cancer, gastric cancer, and gastroesophageal junction cancerFor melanoma, RCC, HNSCC, NSCLC, urothelial carcinoma, CHL, esophageal cancer, and gastroesophageal junction cancer: every two weeks 240 mg
Pediatric patients with MSI-H or dMMR metastatic colorectal cancer: every two weeks 3 mg/kg
Intravenous (i.v.)Back pain, blurred vision, change or loss of taste, depressed mood, cough, dry skin and hair, irregular heartbeat and pulse, loss of appetite, itching, nausea, muscle cramps and stiffness, red, irritated eyes, swelling, redness, the pain of the skin, weight gain, vomiting, chest pain, trouble sleeping, tenderness, bloody or cloudy urine, drowsiness, trouble breathing
Pembrolizumab (brand name “KEYTRUDA®”, humanized IgG4 mAb)Metastatic NSCLC, Metastatic melanoma, urothelial carcinoma, esophageal cancer, PMBCL, HNSCC, MSI-H or dMMR cancer, HCC, gastric cancer, cervical cancer, CHL, RCC, MCC, endometrial carcinoma, TMB-H cancer, triple-negative breast cancer, and CSCCFor adult metastatic melanoma patients: every 3 weeks 200 mg
Adult patients with HNSCC, NSCLC, PMBCL, esophageal cancer, dMMR or MSI-H cancer, cervical cancer, TMB-H, HCC, urothelial carcinoma, MCC, CHL, CSCC: every 3 weeks 200 mg or every 6 weeks 400 mg
Pediatric patients with PMBCL, MSI-H or dMMR cancer, CHL, TMB-H, MCC: every 3 weeks 2 mg/kg
Pediatric melanoma patients: every 3 weeks 2 mg/kg
i.v.Bladder pain, blurred vision, itching, swelling of the face, hands, arms, lower legs, or feet, loss of voice, body aches or pain, confusion, decreased appetite, cough, difficulty with breathing, depressed mood, dry mouth, feeling cold, joint or bone pain, painful or difficult urination, lower back or side pain, slow or fast heartbeat, stomach cramps, vomiting, weakness in the arms, yellow eyes or skin, sneezing, muscle weakness, trouble sleeping, severe or sudden headache, drowsiness
Cemiplimab (brand name “LIBTAYO®”, humanized IgG4 mAb)Metastatic or locally advanced CSCCUntil illness development or toxicity, 350 mg once every three weeksi.v.Diarrhea, fatigue, musculoskeletal pain, rash, nausea, constipation, pruritus, immune-mediated adverse reactions
Atezolizumab (brand name “TECENTRIQ®”, humanized IgG1 mAb)SCLC, urothelial carcinoma, metastatic NSCLC, HCC, and melanomaEvery 3 weeks 1,200 mgi.vNausea, lower back or side pain, difficulty in breathing, diarrhea, body aches or pain, slow and fast heartbeat, burning or painful urination, fever, stomach cramps, rapid weight gain, headache, unusual tiredness or weakness, vomiting, confusion, depressed mood, facial swelling, trouble sleeping, yellow eyes and skin, increased thirst, muscle pain, redness of the skin
Avelumab (brand name “BAVENCIO®”, fully human IgG1 mAb)MCC, RCC, Metastatic urothelial carcinoma10 mg/kg every two weeks until the condition progresses or there is toxicityi.v.Headache, muscle, bone, or joint pain, nausea, constipation, tiredness, vomiting, and weight loss
Durvalumab (brand name “IMFINZI®”, humanized IgG1 mAb)Metastatic urothelial carcinoma, NSCLC, SCLCEvery 2 weeks 10 mg/kgi.v.Bladder pain, fever, dry skin and hair, slowed heartbeat, tenderness, stomach cramps, bloody or cloudy urine, burning, or painful urination, rapid weight gain, chest pain, cough, difficult breathing, sweating, trouble sleeping, blurred vision, headache, chest tightness, pale skin, redness of the eye
Dostarlimab (brand name “JEMPERLI”, humanized IgG4 mAb)dMMR endometrial cancer and dMMR solid tumoursEvery 3 weeks 500 mgi.v.Bladder pain, burning or painful urination, feeling cold, constipation, hair loss, muscle cramps and stiffness, trouble breathing, weight gain, unusual tiredness or weakness, pale skin, chest pain or tightness, confusion, coma, cough, fever, diarrhea, headache, irritability, nausea, trouble sleeping, sweating, anxiety, change in vision, dry mouth, joint pain, drowsiness

CSCC: cutaneous squamous cell carcinoma; MCC: Merkel cell carcinoma; MSI-H: microsatellite instability-high; PMBCL: primary mediastinal large B-cell lymphoma; TMB-H: tumour mutational burden-high cancer